Psilocybin Treatment for Depression

Investigation to Understand and Optimize Psilocybin

Recruiting Phase 2 Interventional Study
Depression
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
141 (estimated)
Sponsor
Charles Raison · Other
Who this trial is looking for

This trial is looking for people with major depression to see how a single dose of psilocybin helps with their symptoms. Participants will receive psychological support and may try different follow-up interventions.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with Major Depressive Disorder.
  • My depressive episode has lasted at least 60 days.
  • I am medically healthy as determined by a doctor.

You may not be able to join if

  • I have a psychiatric condition that could pose a safety risk.
  • I have a family history of a psychotic disorder.
  • I have had active thoughts of suicide in the last 2 weeks.
  • I have attempted suicide in the last 6 months.
  • I have a current substance use disorder.
  • I have an abnormal ECG that may increase risk.
  • I cannot stop taking certain psychiatric medications.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore object…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Current diagnosis of Major Depressive Disorder (MDD), with a depressive episode lasting ≥ 60 consecutive days at the time of screening, as confirmed by structured clinical interview Medically healthy, as determined by the screening physician, with no significant medical conditi…
Contacts

Program Manager

(970) 855-7374

bhic@vailhealth.org

CONTACT